Evidence map›Paper›PMID 26075280›Full record

ArticleBioMed research international2015

A redox-sensitive micelle-like nanoparticle self-assembled from amphiphilic adriamycin-human serum albumin conjugates for tumor targeted therapy.

Lin Chen, Feng Chen, Mengxin Zhao, Xiandi Zhu, Changhong Ke, Jiangming Yu, Zhiqiang Yan, Fulei Zhang, Yun Sun, Di Chen and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Lin ChenDepartment of Medical Oncology, East Hospital, Tongji University, 150 Jimo Road, Shanghai 200120, China.
Feng ChenDepartment of Cardiology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China.
Mengxin ZhaoInternational Joint Cancer Institute, The Second Military Medical University, Shanghai 200433, China.
Xiandi ZhuInternational Joint Cancer Institute, The Second Military Medical University, Shanghai 200433, China.
Changhong KeInternational Joint Cancer Institute, The Second Military Medical University, Shanghai 200433, China.
Jiangming YuDepartment of Orthopaedics, Changzheng Hospital, The Second Military Medical University, No. 415 Fengyang Road, Shanghai 200003, China.
Zhiqiang YanInstitute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics, Shanghai 200062, China.
Fulei ZhangInternational Joint Cancer Institute, The Second Military Medical University, Shanghai 200433, China.
Yun SunInternational Joint Cancer Institute, The Second Military Medical University, Shanghai 200433, China.
Di ChenInternational Joint Cancer Institute, The Second Military Medical University, Shanghai 200433, China.
Cheng JiangInternational Joint Cancer Institute, The Second Military Medical University, Shanghai 200433, China.
Xianxian ZhaoDepartment of Cardiology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China.
Yong GaoDepartment of Medical Oncology, East Hospital, Tongji University, 150 Jimo Road, Shanghai 200120, China.
Shangjing GuoInternational Joint Cancer Institute, The Second Military Medical University, Shanghai 200433, China.
Wei LiInternational Joint Cancer Institute, The Second Military Medical University, Shanghai 200433, China.
Second Military Medical University · CNShanghai East Hospital · CNChanghai Hospital · CNShanghai Institute of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The application of chemotherapeutic drug adriamycin (ADR) in cancer therapy is limited by its side effects like high toxicity and insolubility. Nanomedicine offers new hope for overcoming the shortcomings. But how to increase in vivo stability and to control intracellular drug release is a key issue for nano-based formulations. Herein, the hydrophobic ADR was successfully linked to the biocompatible human serum albumin (HSA) by disulfide bond 3-(2-pyridyldithio) propionyl hydrazide (PDPH), resulting in amphiphilic HSA-ADR. The novel ADR-HSA micellar NPs which were thus assembled exhibited a well-defined stable core shell structure with glutathione (GSH) sensitive linkers. The stable PDPH linkers at extracellular level were broken by GSH at intracellular level with a controlled ADR release profile. The in vitro cytotoxicity against gastric cancer cells (NCI-N87) was obviously enhanced by such redox-sensitive ADR-HSA NPs. Additionally, as observed by IVIS Lumina II Imaging System (Xenogen), the intratumor accumulation of ADR-HSA NPs was much higher than that of HSA/ADR NPs due to its high stability. Consequently, the in vivo tumor inhibition was significantly promoted after intravenous administration to the Balb/c nude mice bearing gastric tumors. These in vitro/vivo results indicated that disulfide-bond-containing ADR-HSA NPs were an effective nanodrug delivery system for cancer therapy.

Indexed as

DoxorubicinSerum AlbuminAnimalsCell Line, TumorDrug Delivery SystemsHumansMiceMice, Inbred BALB CMice, NudeNanoparticlesStomach NeoplasmsXenograft Model Antitumor AssaysDoxorubicinSerum Albumin

Identifiers

PMID26075280
PMCPMC4444569
OpenAlexW1564545012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.